North Carolina Life Science Industry Directory
Target your advertising by state, region or nationwide for the same low rate
Banner Advertising | Event Advertising
Icagen, Inc.
| Icagen, Inc.
4222 Emperor Blvd., Suite 350
Research Triangle Park, NC 27703 | |
| | | | Phone: | (919) 941-5206 | | Fax: | (919) 941-0813 | | Year Established: | 1992 | | Ticker: | PFE | | Exchange: | NYSE | | Main Contact: | Gregory C. Rigdon, Ph.D., Vice President, New Product Development | | | | Other Contacts: | P. Kay Wagoner, Ph.D., President, CEO & Director
Richard D. Katz, M.D., Senior VP, Finance and Corporate Development, CFO & Treasure
Edward P. Gray, J.D., Senior VP, Intellectual Property & Secretary
J. Heyward Hull, III, Pharm.D., M.S., Senior VP, Development and Regulatory Affairs
Douglas Krafte, Ph.D., CSO
| | | | Company Description | Icagen, a wholly-owned subsidiary of Pfizer, is a biopharmaceutical company focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. The Company has a clinical stage program in epilepsy and pain.
On July 20, 2011, Pfizer and Icagen announced their merger agreement whereby Pfizer, which owed 11% of Icagen’s fully diluted shares, acquired the remaining 8.3 million shares at $6.00 per share. The aggregate value, including the value of the shares owned by Pfizer, was $56 million. | |
|
|
